Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/6251
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorHsueh, EC-
dc.creatorKnebel, SM-
dc.creatorLo, WHT-
dc.creatorLeung, TYC-
dc.creatorCheng, PNM-
dc.creatorHsueh, CT-
dc.date.accessioned2014-12-11T08:22:43Z-
dc.date.available2014-12-11T08:22:43Z-
dc.identifier.issn1756-8722-
dc.identifier.urihttp://hdl.handle.net/10397/6251-
dc.language.isoenen_US
dc.publisherBioMed Central Ltd.en_US
dc.rights© 2012 Hsueh et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.subjectArginaseen_US
dc.subjectArgininosuccinate synthetaseen_US
dc.subjectAutophagyen_US
dc.subjectMammalian target of rapamycinen_US
dc.subjectOrnithine carbamoyl transferaseen_US
dc.subjectProstate canceren_US
dc.titleDeprivation of arginine by recombinant human arginase in prostate cancer cellsen_US
dc.typeJournal/Magazine Articleen_US
dc.description.otherinformationAuthor name used in this publication: Wai-Hung Loen_US
dc.description.otherinformationAuthor name used in this publication: Yun-Chung Leungen_US
dc.identifier.spage1-
dc.identifier.epage6-
dc.identifier.volume5-
dc.identifier.doi10.1186/1756-8722-5-17-
dcterms.abstractBackground: Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-proliferative activity in cancer cells deficient in the expression of ornithine carbamoyl transferase (OCT). Interestingly, a variety of cancer cells such as melanoma and prostate cancer deficient in argininosuccinate synthetase (ASS) are sensitive to arginine deprivation by arginine deiminase. In this study, we investigated levels of gene expression of OCT and ASS, and the effects of rhArg in human prostate cancer cells: LNCaP (androgen-dependent), PC-3 and DU-145 (both androgen-independent).-
dcterms.abstractResults: Quantitative real-time PCR showed minimal to absent gene expression of OCT, but ample expression of ASS expression in all 3 cell lines. Cell viability assay after 72-h exposure of rhArg showed all 3 lines had half maximal inhibitory concentration less than or equal to 0.02 U/ml. Addition of ornithine to cell culture media failed to rescue these cells from rhArg-mediated cytotoxicity. Decreased phosphorylation of 4E-BP1, a downstream effector of mammalian target of rapamycin (mTOR), was noted in DU-145 and PC-3 after exposure to rhArg. Moreover, there was no significant apoptosis induction after arginine deprivation by rhArg in all 3 prostate cancer cell lines.-
dcterms.abstractConclusion: rhArg causes significant cytotoxicity in LNCaP, DU-145 and PC-3 prostate cancer cells which all demonstrate decreased OCT expression. Inhibition of mTOR manifested by hypophosphorylation of 4E-BP1 suggests autophagy is involved as alternative cell death mechanism. rhArg demonstrates a promising novel agent for prostate cancer treatment.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationJournal of hematology & oncology, 30 Apr. 2012, v. 5, 17, p. 1-6-
dcterms.isPartOfJournal of hematology & oncology-
dcterms.issued2012-04-30-
dc.identifier.isiWOS:000306596200001-
dc.identifier.scopus2-s2.0-84862187475-
dc.identifier.pmid22546217-
dc.identifier.rosgroupidr58032-
dc.description.ros2011-2012 > Academic research: refereed > Publication in refereed journal-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_IR/PIRAen_US
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Hsueh_Arginine_Recombinant_Cancer.pdf516.75 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

88
Last Week
4
Last month
Citations as of Jun 26, 2022

Downloads

104
Citations as of Jun 26, 2022

SCOPUSTM   
Citations

53
Last Week
0
Last month
0
Citations as of Jun 30, 2022

WEB OF SCIENCETM
Citations

52
Last Week
0
Last month
0
Citations as of Jun 30, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.